HEOR FELLOWSHIP PROGRAM 2023-2025

About Seagen

Seagen is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.

Potential to improve patient outcomes through multiple approaches to targeted therapies

We are developing highly-specific targeted therapies that provide multiple approaches for the treatment of cancer. These include agents that are directed toward receptors on the outside of cells, the signaling pathways within the cell, and the activation of immune cells. These agents may be used as single agents, or as part of combination regimens.

Targeting outside of the cell

Our antibody-drug conjugate technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.

In our ADCs, stable linkers attach a potent synthetic cell-killing (cytotoxic) agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems release the cytotoxic agent once inside the targeted cells. By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects resulting in better outcomes for patients.

Our ADC technology is employed in our approved product, ADCETRIS, and three other programs in pivotal trials, as well as in several earlier-stage candidates.

Targeting pathways inside the cell

Certain signaling pathways in the cell are known to be involved in initiation and progression of cancer. For instance, the kinase signaling pathway has been shown to drive many aspects of cancer tumor biology including survival, motility and evasion of antitumor immune response. We are currently conducting a pivotal trial of an oral tyrosine kinase inhibitor, tucatinib, for patients with an aggressive type of breast cancer.

Activating immune cells

Immunogenic cell death induced by ADCs can result in the stimulation and recruitment of an immune response toward cancer. We believe these properties could make ADCs a preferred partner for immuno-oncology agents, such as checkpoint inhibitors. We are currently conducting several clinical trials combining ADCs with checkpoint inhibitors.

Continuing to advance other approaches

We are conducting phase 1 trials of several novel agents. For example, we have a phase 1 trial evaluating SEA-BCMA, an antibody empowered using our proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody dependent cellular cytotoxicity. The target of SEA-BCMA, the cell surface pro-tein B-cell maturation antigen (BCMA), is broadly expressed on malignant plasma cells in multiple myeloma. SEA-BCMA has demonstrated promising antitumor activity in preclinical studies.

Josh Carlson, MPH, PhD
Professor, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute
School of Pharmacy
University of Washington
Seagen/UW Fellowship Director

---

Zsolt Hepp, PharmD, MS
Senior Director, Global HEOR
Seagen

---

Cindy McDonald-Everett
Senior Vice President, Global Value Access
Seagen

---

A full list of CHOICE Core Faculty, Adjunct Faculty, and Staff can be found here: https://sop.washington.edu/choice/who-we-are/faculty-staff/

A full list of CHOICE Affiliate Faculty can be found here: https://sop.washington.edu/choice/who-we-are/faculty-staff/affiliate-faculty/

Seagen and the University of Washington Comparative Health Outcomes, Policy and Economics (CHOICE) Institute now offer a 2-year health economics and outcomes research (HEOR) fellowship for post-PharmD students. Designed to help meet the growing need for expertise in HEOR and evaluation of pharmaceuticals and other health care technologies, the fellowship combines 1 year of academic study with 1 year of industry experience to provide both the theoretical tools and the practical experience to become a skilled researcher in this increasingly important field.

Fellows will receive a competitive stipend for each year of the fellowship, along with tuition, health benefits, and travel expenses for company meetings and attendance at 1 domestic professional meeting per year.

Fellowship Program Objectives

After completion of the 2-year program, fellows will have a clear understanding of:

• General principles of economics and how economics influences the use, cost, and availability of pharmaceuticals.
• The complex structure of drug policy and how it determines relationships among consumers, health care providers, payers, and government agencies.
• The breadth, scope and limitations of analytical methods needed for assessing cost-effectiveness and health-related quality-of-life as influenced by the use of pharmaceuticals.
• Research design and epidemiology methodology, including development of research protocols in pharmaceutical-related outcomes assessment.
• Formulary development, maintenance and evaluation in institutional, managed care, and state-level government programs.

Fellows shall also gain practical experience in:

• Designing an economic assessment protocol and conducting the research, as applied to either existing products or those in development.
• Applying the methods of epidemiology, statistics, and psychometrics as they relate to cost-effectiveness and health-related quality-of-life evaluations.
• Preparing proposals for funding research in an academic, government, or industry setting.
• Disseminating results of an economic assessment by preparation of a manuscript, seminar, or other scholarly vehicle as well as a US FDAMA 114/Section 3037 approved health care economic information communication.
• Application of HEOR methods to inform pharmaceutical research strategies.

Fellowship Program 1st Year

The first year of the fellowship is conducted at the University of Washington School of Pharmacy in Seattle. The objective of the first year is to learn the foundations of health economics and outcomes research, including an overview of pharmaceutical economics, general health policy, economic assessment methodologies, health services research design, and statistical analysis through an individualized program of coursework provided through the University of Washington in consultation with the program director.

Fellows will meet regularly with their advisor to discuss their progress and review assigned current research articles. In addition to their classwork, fellows will participate in a research seminar designed to provide them with experience in critiquing, preparing, and presenting scholarly research during each quarter and will be expected to present a report on their independent research once during that year. The program is rigorous, requiring up to 45 hours a week in classwork and independent study.

Fellows will be required to develop, under the guidance of their advisors at the University of Washington and Seagen, a research project leading to a thesis. The fellow will choose the topic, with input from the University of Washington and Seagen and should be of mutual interest to all parties. If the selected topic involves a Seagen compound, the research protocol will be submitted to Seagen for prior approval. Additional funding to complete this project may be made available at the discretion of Seagen. Research proposals shall be implemented while fellows are at the University of Washington but may continue into the second year of the program. Research will be managed by fellows under the supervision of University of Washington faculty and Seagen product researcher(s).

Due to the proximity of Seagen to the University of Washington, fellows can regularly interact with Seagen staff while focusing attention on their coursework. This provides unique early exposure to the Seagen team in advance of the second year industry placement.

Fellowship Program 2nd Year

The second year provides fellows experience in applying the HEOR skills gained during their first year of the program to real-world development and commercialization of a product within the industry setting.

The fellow will work on site at Seagen as a member of the HEOR team. Fellows gain hands-on experience in conducting research with an oncology focus, approved by both Seagen and the University of Washington, to support the evidence generation plan of an existing or experimental product in a therapeutic area of interest to Seagen.

Unique to the Seagen Fellowship is its focus on oncology, and the opportunity to learn the real-world evidence and value strategy needed to support new oncology treatments. Fellows will learn how pharmacoeconomics and outcomes research are developed with consideration for value frameworks such as those produced by the American Society of Clinical Oncologists (ASCO), the National Comprehensive Cancer Network (NCCN), and the Institute for Comparative Effectiveness Research (ICER).

In addition to completing their individual research project(s), fellows will participate in ongoing pharmacoeconomic evaluations or other outcomes projects assigned by their Seagen preceptor. They will have the opportunity to interact with Seagen clinical research, commercial development, and regulatory affairs teams to learn how Seagen uses diverse datasets and HEOR methodologies to generate evidence needed to identify unmet need and demonstrate Seagen product value to payers, providers, and patients. Fellows will be expected to present the results of any individual research projects to the University of Washington faculty, graduate students, other post-doctoral fellows, and to cross-functional teams at Seagen. After completion of the program, fellows will have a solid understanding of HEOR methodologies as well as firsthand experience in applying their learnings in an industry setting, laying the foundation for a successful career in HEOR.

Application Requirements

• You must hold U.S. citizenship or permanent residency status to apply, we are unable to sponsor non-immigrant visas for this program.
• Degree in pharmacy or health-related discipline.
• Previous research experience (preference will be given to those with a high academic standing).
• Excellent oral and written communication skills, ethics, professionalism, leadership and an interest in the biopharmaceutical industry.
• Curriculum vitae, cover letter, three letters of recommendation.

Selection of fellows will be made by a committee composed of University of Washington faculty members and representatives from the respective company.

Note: for the current application cycle (2023 entry) the UW will not be holding fellowship interviews at the American Society of Hospital Pharmacists (ASHP) Midyear Clinical Meeting. Video interviews will be coordinated internally the week of November 7 by Zoom.

Application Process Timeline:

• Eligibility: Degree in Pharmacy by July 1, 2023
• Application Deadline: Friday, October 28, 2022
• Interview Notification: Wednesday, November 2, 2022
• Interviews: Week of November 7, 2022
• Offer Notification: Friday, November 11, 2022 — decisions requested by Nov 14 and 15
• Program Start Date: July 1, 2023

How to Apply

• Apply directly through the University of Washington Graduate School Application
• Start your Graduate School application
  • Scroll down and select Create a Profile under the heading New Applicants
• Create your Applicant Profile
• Once completed, select Create a new application
• Select the following for each category:
  • Application type: Graduate
  • Program: Pharmacy — Health Economics & Outcomes Research (MS)
  • Quarter and Year: Fall 2023
  • Areas of Interest: AbbVie Fellowship Program, Bayer Fellowship Program, Genentech Fellowship Program, Seagen Fellowship Program (select all that apply). 
    • Note: This step is very important! It tells us which positions you are applying to with the single Graduate School application.
• Complete all steps in the application including:
  • Report Prior Schools
  • Submit Transcripts (upload your unofficial transcripts)
  • Submit Resume or Vitae
  • Designate Recommendations (enter the email address of your 3 recommenders who will be notified as soon as you enter their information to submit a recommendation on your behalf)
  • Submit Statement of Purpose
  • Review Checklist of Application Materials
• Verify, Pay, and Submit the Application no later than October 28, 2022!

Contact Information

For more information, please contact:

University of Washington

Marina Gano, M.Ed.
Graduate Program & Operations Manager
The CHOICE Institute, Department of Pharmacy
206-616-1383
uwsopchoice@uw.edu

Bettina Schifferl, M.A.
Program Operations Specialist
206-685-9203
uwsopchoice@uw.edu

Dr. Zsolt Hepp
Seagen
(425) 527-2561
zhepp@seagen.com